Shortage Watch Free FDA drug-shortage watch

← all medications

Tazemetostat Hydrobromide Tablet

Brand names: Tazverik

Category: Oncology

Not specified 1

FDA status: To Be Discontinued · Last FDA update: Mar 27, 2026 · First posted: Mar 27, 2026 · 1 manufacturers, 1 listed presentations

As of Mar 27, 2026, the FDA lists Tazemetostat Hydrobromide Tablet as being discontinued. Of 1 manufacturer presentations, 1 Not specified.

Ask your pharmacist: which of the 1 manufacturers below can they order right now, and whether a different strength or form of Tazemetostat Hydrobromide Tablet is available. For alternatives, talk to your prescriber — see what to do if your medication is in shortage.
Presentation & package NDCManufacturerAvailabilityFDA note
Tazverik, Tablet, 200 mg (NDC 72607-100-00)
NDC 72607-100-00		 Epizyme, Inc. (An Ipsen Company) Not specified Discontinuation of the manufacture of the drug product

Related medications in shortage

Other Oncology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.

Change log

No changes recorded yet.
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.

Cite this: “FDA drug-shortage status for Tazemetostat Hydrobromide Tablet (FDA data as of Mar 27, 2026). Shortage Watch, openFDA.”

Get an email when this record changes

One email, only when the FDA changes something for Tazemetostat Hydrobromide Tablet. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.

Check your inbox - click the confirmation link to activate alerts for Tazemetostat Hydrobromide Tablet.

Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.

Embed a live status badge: /badge/tazemetostat-hydrobromide-tablet.svg

FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).